Physician profile
Michael J Rasansky
NPI 1902923733
$4,161.45
in general payments reported to CMS, 2019-2025
25 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $264 · 2021: $418 · 2022: $622 · 2023: $570 · 2024: $1,505 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,671 · Travel and Lodging: $956 · Entertainment: $72.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.79 |
| Travel and Lodging | $955.78 |
| Entertainment | $72.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,387.48 | 2019-2025 | Lensx, Clareon, Argos |
| Tarsus Pharmaceuticals, INC. | $199.75 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $159.72 | 2023-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $124.99 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Oyster Point Pharma, INC. | $121.64 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $105.83 | 2020-2025 | |
| Omeros Corporation | $96.58 | 2020-2021 | |
| New World Medical,INC. | $95.72 | 2021-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Sight Sciences, INC. | $88.24 | 2019-2025 | Omni Surgical System |
| Rxsight INC | $83.72 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $80.62 | 2020-2022 | |
| Aerie Pharmaceuticals, INC. | $79.02 | 2019-2021 | |
| Optos, INC. | $72.05 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $64.49 | 2023-2025 | |
| Rayner Intraocular Lenses Limited | $62.01 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $59.56 | 2021-2022 | |
| Biotissue Holdings INC. | $51.11 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.72 | 2019 | |
| Thea Pharma INC. | $42.52 | 2025 | Iyuzeh |
| Beaver-Visitec International, INC. | $30.18 | 2020 | |
| Mallinckrodt Hospital Products INC. | $26.73 | 2021 | |
| Amgen INC. | $26.24 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $22.15 | 2019 | |
| Astellas Pharma US INC | $19.68 | 2023 | Izervay |
| Horizon Therapeutics Plc | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rasansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.